The Motley Fool Previous Page


Why Arena Pharmaceuticals, Santarus, and Universal Display Soared Today

http://www.fool.com/investing/general/2013/11/08/why-arena-pharmaceuticals-santarus-and-universal-d.aspx

Dan Caplinger
November 8, 2013

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

Yesterday's concerns about the state of the economy turned into resounding optimism today, as stock markets soared in response to a bigger jump in job creation during October than economists had expected. The bullish sentiment was especially obvious in shares of Arena Pharmaceuticals (NASDAQ: ARNA), Santarus (NASDAQ: SNTS), and Universal Display (NASDAQ: OLED), which all posted double-digit percentage gains. Let's look at each of these stocks to see what sent them soaring today.

Arena Pharmaceuticals climbed more than 17% in the wake of the company's third-quarter earnings report. Revenue soared by 140%, although the company's net loss widened from year-ago levels. Much more importantly, though, Arena announced that it would expand its marketing and supply agreement with Japan's Eisai for its Belviq obesity drug, with Arena receiving an upfront $60 million payment in exchange for exclusive commercialization rights nearly worldwide, with the exception of five countries. In the U.S., Eisai will double its sales force in an effort to reach 65,000 doctors nationwide, and will also launch a magazine ad campaign. Investors clearly hope that Eisai's redoubled effort will boost sales, and that Arena will receive further milestone payments under the agreement.

Santarus led the gainers list with a